Dr. Keshu Zhou 周可树
Chief Physician
Department of Hematology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Treatment and research of lymphatic system diseases.
Dr. Zhou holds a doctoral degree and serves as Chief Physician. Dr. Zhou received first prize in the Henan Medical Science and Technology Progress Award and leads a National Natural Science Foundation general project. In the past five years, Dr. Zhou published three SCI papers and over ten articles in Chinese core journals, and co-authored three monographs.
Professional roles
- Member, Lymphoma Professional Committee, Henan Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhou Keshu). Papers usually list the name as Keshu Zhou or Zhou K.
Selected publications
82 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Case Report: Frontline CD19 CAR-T-cell therapy combined with targeted regimens induces durable complete remission in newly diagnosed secondary CNS lymphoma: a report of two cases. PubMed 42819140
- Cancer Biol Med, 2025 (first author): Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study. PubMed 41025431
- Ann Hematol, 2024 (first author): Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE. PubMed 38888616
- J Chem Inf Model, 2024 (senior author): Discovery of a Novel and Potent LCK Inhibitor for Leukemia Treatment via Deep Learning and Molecular Docking. PubMed 38847742
- Exp Hematol Oncol, 2024 (senior author): Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting. PubMed 38413984
- Biochem Biophys Res Commun, 2023 (senior author): Upregulation of USP25 promotes progression of human diffuse large B-cell lymphoma through blocking the ubiquitinated degradation of MDM2. PubMed 37480689
- Front Immunol, 2022 (senior author): Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. PubMed 36311747
- Front Immunol, 2022 (senior author): Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph(+) B cell acute lymphoblastic leukemia. PubMed 36225940
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion